These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 7887070)

  • 1. An economic model for comparing alternative policies for cervical cytologic smear screening.
    Kaminsky FC; Burke RJ; Haberle KR; Mullins DL
    Acta Cytol; 1995; 39(2):232-8. PubMed ID: 7887070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescreening policies in cervical cytology and their effect on detecting the truly positive patient.
    Kaminsky FC; Burke RJ; Haberle KR; Mullins DL
    Acta Cytol; 1995; 39(2):239-45. PubMed ID: 7887071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical analysis of data in cervical cytology from the viewpoint of total quality management.
    Kaminsky FC; Burke RJ; Haberle KR; Mullins DL
    Acta Cytol; 1995; 39(2):222-31. PubMed ID: 7887069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A more accurate measure of the false-negative rate of Papanicolaou smear screening is obtained by determining the false-negative rate of the rescreening process.
    Renshaw AA; DiNisco SA; Minter LJ; Cibas ES
    Cancer; 1997 Oct; 81(5):272-6. PubMed ID: 9349513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Partial re-screening of all negative smears. A method of quality control of pathology department concerning smear screening against cervix cancer].
    Jensen ML; Dybdahl H; Svanholm H
    Ugeskr Laeger; 2000 May; 162(21):3024-7. PubMed ID: 10850190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of 100% rapid rescreening of negative cervical smears as a quality assurance measure.
    Manrique EJ; Amaral RG; Souza NL; Tavares SB; Albuquerque ZB; Zeferino LC
    Cytopathology; 2006 Jun; 17(3):116-20. PubMed ID: 16719853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical trial of the AutoPap 300 QC system for quality control of cervicovaginal cytology in the clinical laboratory.
    Colgan TJ; Patten SF; Lee JS
    Acta Cytol; 1995; 39(6):1191-8. PubMed ID: 7483997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of PAPNET--a semiautomated system used in the screening against cervical cancer].
    Hølund B; Ejersbo D; Hjortebjerg A
    Ugeskr Laeger; 1998 Sep; 160(40):5802-6. PubMed ID: 9782761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid prescreening of Papanicolaou smears: a practical and efficient quality control strategy.
    Djemli A; Khetani K; Auger M
    Cancer; 2006 Feb; 108(1):21-6. PubMed ID: 16302251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of AutoPap system-assisted and manual cytologic screening. A comparison.
    Wertlake P
    J Reprod Med; 1999 Jan; 44(1):11-7. PubMed ID: 9987733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the financial impact of covering new screening technologies. The case of automated Pap smears.
    McQuarrie HG; Ogden J; Costa M
    J Reprod Med; 2000 Nov; 45(11):898-906. PubMed ID: 11127101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated screening versus manual screening: a comparison of the ThinPrep imaging system and manual screening in a time study.
    Schledermann D; Hyldebrandt T; Ejersbo D; Hoelund B
    Diagn Cytopathol; 2007 Jun; 35(6):348-52. PubMed ID: 17497655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PAPNET system for quality control of cervical smears: validation and limits.
    Cenci M; Nagar C; Giovagnoli MR; Vecchione A
    Anticancer Res; 1997; 17(6D):4731-4. PubMed ID: 9494597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical carcinoma in situ undetected by Papanicolaou smear but identified by cervicography. A case report.
    Ferris DG
    J Fam Pract; 1994 Jan; 38(1):74-7. PubMed ID: 8289055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The false-negative fraction for Papanicolaou smears: how often are "abnormal" smears not detected by a "standard" screening cytologist?
    Naryshkin S
    Arch Pathol Lab Med; 1997 Mar; 121(3):270-2. PubMed ID: 9111116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of cervical-vaginal rescreening.
    Raab SS
    Am J Clin Pathol; 1997 Nov; 108(5):525-36. PubMed ID: 9353091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of a semiautomated Papanicolaou smear screening system: results of a population-based study conducted in Guanacaste, Costa Rica.
    Sherman ME; Schiffman M; Herrero R; Kelly D; Bratti C; Mango LJ; Alfaro M; Hutchinson ML; Mena F; Hildesheim A; Morales J; Greenberg MD; Balmaceda I; Lorincz AT
    Cancer; 1998 Oct; 84(5):273-80. PubMed ID: 9801201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ThinPrep Papanicolaou testing to reduce false-negative cervical cytology.
    Linder J; Zahniser D
    Arch Pathol Lab Med; 1998 Feb; 122(2):139-44. PubMed ID: 9499356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of blinded rescreening of Papanicolaou smears versus biased retrospective review.
    Austin RM
    Arch Pathol Lab Med; 1997 Mar; 121(3):311-4. PubMed ID: 9111125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The PAPNET system in cytological rescreening of cervical smears].
    Cenci M; Nagar C; Giovagnoli MR; Vecchione A
    Minerva Ginecol; 1997 Apr; 49(4):139-45. PubMed ID: 9206764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.